Stock listing

LSE:RENX Renalytix PLC Share Price

Home listing (LSE) of Renalytix PLC

Follow Renalytix PLC into a list and get an email when it puts out news.

Share price · LSE:RENX

5.20p GBX (pence) -0.15 (-2.8%)

Close on Nov 20, 2026

Past year -23.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
5.01p – 5.50p GBX (pence)Nov 20, 2026
Volume
1.15M sharesNov 20, 2026
Market cap
£34.86M GBPAt the close on Nov 20, 2026 · price × 670.5M shares outstanding
52-week range
1.60p – 7.00p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
£78,687 GBPMedian day 614,627 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Renalytix PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:RENX · Home5.20p GBX (pence)-0.15 (-2.8%)1,152,2295.35p5.50p5.01p5.35pClose on Nov 20, 2026
OTC:RNLXY$3.45 USD-0.05 (-1.4%)100$3.45$3.45$3.45$3.50Close on Nov 20, 2026
OTC:RENXF$0.066 USD0.000 (0.0%)—$0.066$0.066$0.066$0.066Close on Nov 6, 2026
Frankfurt:2O9€0.061 EUR-0.001 (-0.8%)—€0.061€0.061€0.061€0.061Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:RENX · GBX (pence), adjusted for splits

DayCloseChange%OpenHighLowVolume
5.20p-0.15-2.8%5.35p5.50p5.01p1,152,229
5.35p0.000.0%5.35p5.50p5.32p55,216
5.35p-0.05-0.9%5.40p5.50p5.215p644,990
5.40p0.000.0%5.40p5.40p5.303p46,134
5.40p0.000.0%5.40p5.60p5.281p193,359
5.40p0.000.0%5.40p5.465p5.25p163,589
5.40p0.000.0%5.40p5.60p5.40p219,557
5.40p-0.05-0.9%5.45p5.60p5.272p863,587
5.45p-0.05-0.9%5.50p5.52p5.30p337,776
5.50p-0.05-0.9%5.55p5.70p5.321p494,824
5.55p0.000.0%5.55p5.70p5.40p283,416
5.55p+0.10+1.8%5.50p5.58p5.413p131,426
5.45p0.000.0%5.45p5.48p5.394p369,695
5.45p0.000.0%5.45p5.54p5.363p448,082
5.45p0.000.0%5.45p5.60p5.30p1,144,502
5.45p-0.15-2.7%5.60p5.70p5.428p595,142
5.60p-0.35-5.9%5.64p5.64p5.153p2,984,229
5.95p0.000.0%5.95p6.05p5.804p614,627
5.95p-0.05-0.8%6.00p6.10p5.90p914,170
6.00p+0.20+3.4%5.80p6.10p5.60p2,483,906
5.80p+0.45+8.4%5.35p5.90p5.20p2,900,799
5.35p0.000.0%5.35p5.475p5.20p266,695
5.35p-0.10-1.8%5.45p5.50p5.21p1,155,417
5.45p0.000.0%5.45p5.487p5.30p184,469
5.45p0.000.0%5.45p5.50p5.30p253,730
5.45p0.000.0%5.45p5.60p5.30p1,439,646
5.45p+0.10+1.9%5.35p5.54p5.30p99,467
5.35p0.000.0%5.35p5.60p5.10p350,049
5.35p+0.05+0.9%5.30p5.60p5.10p795,886
5.30p-0.20-3.6%5.40p5.50p5.10p1,404,443
5.50p-0.30-5.2%5.80p6.00p5.15p1,657,860
5.80p-0.15-2.5%5.95p6.00p5.70p439,972
5.95p-0.05-0.8%6.00p6.20p5.728p695,636
6.00p0.000.0%6.00p6.20p5.80p194,466
6.00p0.000.0%6.00p6.09p5.80p880,986
6.00p-0.10-1.6%6.05p6.30p5.80p1,200,742
6.10p+0.05+0.8%6.05p6.30p5.80p2,385,600
6.05p-0.10-1.6%6.15p6.30p5.752p3,019,439
6.15p0.000.0%6.15p6.50p5.80p788,003
6.15p0.000.0%6.15p6.15p5.835p452,742
6.15p+0.15+2.5%6.15p6.15p5.80p75,944
6.00p-0.25-4.0%6.25p6.50p5.88p465,342
6.25p0.000.0%6.25p6.25p6.00p1,466,487
6.25p0.000.0%6.25p6.50p6.00p378,529
6.25p+0.10+1.6%6.15p6.50p5.80p506,370
6.15p-0.10-1.6%6.25p6.50p6.00p776,610
6.25p+0.30+5.0%5.85p6.497p5.50p962,040
5.95p-0.45-7.0%6.30p6.40p5.70p1,174,315
6.40p+0.10+1.6%6.35p6.57p6.20p7,794,978
6.30p+0.70+12.5%5.60p6.50p5.50p16,158,342
5.60p+0.20+3.7%5.40p6.00p5.20p2,530,386
5.40p0.000.0%5.35p5.70p5.20p7,080,792
5.40p+1.25+30.1%5.75p6.00p5.00p4,422,050
4.15p0.000.0%4.15p4.15p4.15p0
4.15p0.000.0%4.15p4.30p4.03p54,960
4.15p-0.10-2.4%4.25p4.30p4.00p470,800
4.25p-0.05-1.2%4.30p4.30p4.20p83,188
4.30p+0.05+1.2%4.25p4.675p4.20p2,370,623
4.25p+0.40+10.4%3.85p4.50p3.70p928,053
3.85p-0.05-1.3%3.90p4.00p3.70p131,184
3.90p-0.05-1.3%3.95p4.10p3.70p290,150
Ticker
LSE:RENX
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
LSE
Currency
GBX

What changed lately

Latest news

Notice of 2026 Annual General Meeting

Nov 18, 2026

Closed 5.35p (0.0%) on Nov 18, 2026

Holding(s) in Company

Nov 16, 2026

Closed 5.35p (-0.9%) on Nov 17, 2026

Publication of Equity Research

Nov 9, 2026

Closed 5.45p (-0.9%) on Nov 9, 2026

US Kidney Care National Plan

Oct 22, 2026

Closed 5.80p (+8.4%) on Oct 22, 2026

Director/PDMR Shareholding (Replacement)

Oct 2, 2026

Closed 6.00p (0.0%) on Oct 5, 2026

Director/PDMR Shareholding

Oct 1, 2026

Closed 6.00p (0.0%) on Oct 2, 2026

All Renalytix PLC news

Renalytix PLC on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
36 in the last 12 months · 279 in all · newest Nov 18, 2026 · oldest 2018
Calls
17 calls with a replay · 17 with a transcript · latest Sep 29, 2026
Decks
2 decks · latest September 2025

Where Renalytix PLC is listed

ListingExchangeCountryCurrency
LSE:RENX · Home listing · This pageLSEUnited KingdomGBX
OTC:RNLXYOTCUnited StatesUSD
LS Exchange:A2N765LS ExchangeGermanyEUR
gettex:2O9gettexGermanyEUR
Aquis:RENXLAquisUnited KingdomGBX
OTC:RENXFOTCUnited StatesUSD
Frankfurt:2O9FrankfurtGermanyEUR
Frankfurt:2O90FrankfurtGermanyEUR
gettex:A41WQDgettexGermanyEUR
Lang & Schwarz:A2N765Lang & SchwarzGermanyEUR
Lang & Schwarz:A41WQDLang & SchwarzGermanyEUR
LS Exchange:A41WQDLS ExchangeGermanyEUR
Munich:2O9MunichGermanyEUR
Stuttgart:2O9StuttgartGermanyEUR

Valuation

EV/sales 15.1× against a median of 1.2×: 10th lowest of 11 Diagnostics & research services companies shown. Statements: Year to Jun 30, 2025 · balance Dec 31, 2025 · price Nov 20, 2026

Enterprise value
£34.56M GBP
P/E
Loss
EV/sales
15.1×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
40.0%
Operating margin
−573.3%
Net margin
−680.0%
Debt to equity
Negative equity
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Renalytix PLC · LSE:RENXUS$45.66MUS$45.26Mn/a15.1×n/an/a−680.0%n/an/a
Celemics, Inc. · KRX:331920US$49.19MUS$32.45Mn/a8.4×n/a2.2×−260.9%0.5×n/a
Lumos Diagnostics Holdings Ltd. · ASX:LDXUS$47.13MUS$37.64Mn/a2.8×n/a2.1×−37.5%0.3×n/a
Labiana Health SA · BME:LABUS$44.35MUS$70.57M15.7×0.9×5.8×8.0×3.4%5.9×n/a
Access Bio, Inc. · KRX:950130US$44.15M−US$191.0Mn/a−10.8×n/a0.1×−468.1%0.0×n/a
EDX Medical Group plc · LSE:EDXUS$43.78MUS$39.96Mn/a92.3×n/a15.4×n/a0.0×n/a
Osang Healthcare Co. Ltd. · KRX:036220US$42.35MUS$24.18Mn/a0.3×n/a0.2×−8.8%0.1×n/a
ABL Diagnostics SA · EURONEXT:ABLDUS$41.27MUS$42.32M38.1×5.5×42.8×5.3×14.2%0.3×n/a
hVIVO plc · LSE:HVOUS$41.02MUS$42.24Mn/a0.7×7.5×1.0×−12.8%0.4×n/a
Harvard Bioscience, Inc. · NASDAQ:HBIOUS$39.60MUS$71.90Mn/a0.8×28.4×7.8×−13.2%7.3×1.34
CytoGen, Inc. · KRX:217330US$38.58MUS$31.66Mn/a1.6×n/a1.6×−38.5%0.4×n/a
Median of the othersUS$43.06MUS$38.80M26.9×1.2×18.0×2.1×−13.2%0.3×1.34

Team and board

Officers

OfficerRole
James McCulloughMBA, CEO
Joel R. JungMBA, Interim CFO
Howard DoranPresident
Elise WilfingerChief Strategy & Marketing Officer
Fergus FlemingCTO
Michael J. DonovanChief Medical Officer

Board

DirectorRole
Julian BainesChairman
Catherine Coste
Christopher Mills
Erik LiumBoard Member
Robert Naylor

Events

Calls

CallWhenStatus
Renalytix (LSE:RENX) — Company UpdateTue, Sep 29, 2026 · 11:00 AM ETReplay
Renalytix (LSE:RENX) Q2 2025 Earnings CallTue, Mar 18, 2025 · 8:30 AM ETReplay
Renalytix (LSE:RENX) Q3 2024 Earnings CallWed, May 15, 2024 · 8:30 AM ETReplay
Renalytix (LSE:RENX) Q1 2024 Earnings CallTue, Nov 14, 2023 · 8:30 AM ETReplay
Renalytix (LSE:RENX) Q4 2023 Earnings CallThu, Sep 28, 2023 · 8:30 AM ETReplay
Renalytix (LSE:RENX) Q3 2023 Earnings CallFri, Jun 09, 2023 · 8:30 AM ETReplay
Renalytix (LSE:RENX) Q2 2023 Earnings CallThu, Mar 30, 2023 · 8:30 AM ETReplay
Renalytix (LSE:RENX) Q1 2023 Earnings CallWed, Nov 30, 2022 · 8:30 AM ETReplay
Renalytix (LSE:RENX) Q4 2022 Earnings CallMon, Oct 31, 2022 · 8:30 AM ETReplay
Renalytix (LSE:RENX) Q3 2022 Earnings CallThu, Jun 30, 2022 · 8:30 AM ETReplay
All 17 calls
CallWhenStatus
Renalytix (LSE:RENX) Q2 2022 Earnings CallThu, Mar 31, 2022 · 8:30 AM ETReplay
Renalytix (LSE:RENX) Q1 2022 Earnings CallTue, Dec 07, 2021 · 8:30 AM ETReplay
Renalytix (LSE:RENX) Q4 2021 Earnings CallThu, Oct 21, 2021 · 8:30 AM ETReplay
Renalytix (LSE:RENX) Q3 2021 Earnings CallTue, Jun 15, 2021 · 8:30 AM ETReplay
Renalytix (LSE:RENX) Q2 2021 Earnings CallTue, Mar 02, 2021 · 8:30 AM ETReplay
Renalytix (LSE:RENX) — Financial results for the full year ended June 30, 2020Tue, Oct 27, 2020 · 12:30 PM ETReplay
Renalytix (LSE:RENX) Q4 2020 Earnings CallTue, Oct 27, 2020 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Quarter to Mar 31, 2026May 13, 20260.0%
Quarter to Sep 30, 2025Nov 4, 2025−1.8%
Quarter to Mar 31, 2025Jun 17, 20250.0%
Q2 2025Mar 18, 2025 · Before open0.0%
Q1 2025Oct 1, 2024 · Before open+6.3%
Q3 2024May 15, 2024 · After close0.0%
Q2 2024Feb 15, 2024 · After close−10.9%
Q1 2024Nov 14, 2023 · Before open−26.7%
Q4 2023Sep 28, 2023 · Before open−25.8%
Q3 2023Jun 9, 2023 · Before open−5.7%
All 18 quarters
QuarterResultsShare move
Q2 2023Mar 30, 2023 · After close−2.9%
Q1 2023Nov 30, 2022 · Before open+6.9%
Q4 2022Sep 30, 2022−2.5%
Q3 2022Jun 30, 2022 · Before open−37.3%
Q2 2022Mar 31, 2022 · Before open0.0%
Q1 2022Dec 7, 2021−2.7%
Q3 2021Jun 15, 2021+2.2%
Q2 2021Mar 2, 2021+2.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2025)Investor deck10 slidesSeptember 2025
H1 FY2025 Earnings PresentationEarnings18 slidesMarch 2025

Open Decks

Financings

RaiseDateIn US dollars
Retail Offer Shares
Closed: £1M raised · £0.06 a share
Sep 28, 2026US$1.35M
Private placement of new ordinary shares
Closed: £10.1M raised · £0.06 a share · Oberon Capital +1
Dealers: Oberon Capital (lead), SP Angel Corporate Finance LLP
Sep 28, 2026US$13.66M
Private placement of new Ordinary Shares
Closed: £7.05M raised · GBX 9.5 a share · Oberon Capital +2
Dealers: Oberon Capital (lead), SP Angel Corporate Finance LLP, Winterflood Securities Ltd
Buyers: Julian Baines (105,263 shares; 0.48% post Admission); Christopher Mills (2,500,000 shares; 4.21% post Admission); Robert Naylor (105,263 shares; 0.17% post Admission); Catherine Coste (105,263 shares; 0.1% post Admission)
Insiders: Directors Julian Baines, Christopher Mills, Robert Naylor and Catherine Coste participated in the Fundraise
Use of proceeds: Support growth and the new collaboration with Tempus AI
Sep 26, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Renalytix AI plc. Final prospectus filed on Jul 17, 2020.

Shares offered
11,000,000 ordinary shares
Underwriters' option
Up to 822,750 more shares
Underwriters
J.P. Morgan, Stifel · In the order on the cover
Shares delivered
On or about Jul 21, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceMay 15, 2020
Filed publiclyJun 24, 2020
Amended onceJul 13, 2020
Shares registered with an exchangeJul 13, 2020
Declared effective by the SECJul 16, 2020
Final prospectus, with the priceJul 17, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Jul 17, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue3.00M2.29M3.40M2.97M1.49M0
Cost of revenue1.80M2.13M2.68M2.10M858.0K0
Gross profit1.20M156.0K720.0K874.0K633.0K0
Research and development900.0K9.29M14.3M14.6M10.0M4.57M4.32M
Selling, general and administrative4.90M19.8M28.7M13.0M8.37M1.25M
Operating income-17.2M-29.6M-42.2M-53.2M-31.9M-10.3M-42.3M-418.0K
Depreciation and amortization0364.0K508.0K489.0K282.0K70.0K31.0K1.25M
EBITDA-17.2M-29.2M-41.7M-52.7M-31.6M-10.2M-42.3M836.0K
Interest expense500.0K02.00K2.00K3.00K
Income before tax-21.8M-33.5M-45.6M-45.3M-35.3M-9.84M-42.3M-418.0K
Income tax-1.40M4.00K2.00K25.0K00
Net income-20.4M-33.5M-45.6M-45.3M-35.3M-9.84M-42.3M-1.25M
Earnings per share, basic-0.21-0.31-0.55-0.62-0.49-0.17-0.99-0.03
Earnings per share, diluted-0.31-0.55-0.67-0.49-0.17-0.99

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents3.60M4.68M24.7M41.3M65.1M13.3M8.20M41.5K
Short-term investments100.0K700.0K1.46M2.74M0982.0K994.0K
Receivables600.0K722.0K776.0K901.0K594.0K15.1K
Inventory200.0K300.0K718.0K1.16M353.0K-7.00K
Current assets5.80M6.12M26.9M44.8M66.8M14.8M9.42M56.6K
Property, plant and equipment216.0K1.03M1.37M2.49M1.66M278.0K
Goodwill23.1B23.1B23.1B
Total assets6.10M7.97M30.6M50.1M78.6M20.9M9.70M56.6K
Accounts payable2.60M2.61M2.94M1.38M1.40M2.22M317.0K10.0K
Current liabilities4.80M11.5M16.1M11.8M7.06M3.29M1.15M66.0K
Long-term debt8.30M4.33M7.49M7.68M0
Total debt8.30M8.54M12.2M12.3M352.0K66.0K
Total liabilities13.1M15.8M23.7M19.5M7.12M4.97M1.15M66.0K
Shareholders' equity-7.00M-7.85M6.97M30.6M71.5M15.9M8.55M-349.0K
Shares outstanding97.3M154.4M93.8M74.8M72.2M59.4M53.8M41.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-17.9M-30.1M-34.1M-45.9M-28.4M-9.52M-6.16M-422.0K
Capital spending-6-4.00K0-557.0K-773.0K-804.0K-309.0K0
Free cash flow-17.9M-30.1M-34.1M-46.5M-29.2M-10.3M-6.46M-422.0K
Cash from investing-4.00K0-662.0K-751.0K-1.17M-12.3M
Cash from financing16.0M10.3M16.4M25.6M77.2M15.9M27.4M504.0K
Dividends paid-4.64B-5.10B-5.23B
Share buybacks-1.62B-3.44B5.23B
Change in cash-1.10M-20.0M-16.7M-23.8M51.8M5.09M8.12M82.0K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13D/A · Big-stake notice, amendedFeb 23, 2026Big-stake noticeSEC
F-6 POSDec 3, 2025Other filingsSEC
F-6 POSSep 4, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJul 31, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJul 31, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJul 31, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJul 31, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJul 31, 2025Other filingsSEC
424B3 · ProspectusJul 30, 2025Offer documentSEC
15-12GJul 30, 2025Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
POS AM · Amendment to an effective registrationJul 29, 2025Offer documentSEC
POS AM · Amendment to an effective registrationJul 29, 2025Offer documentSEC
POS AM · Amendment to an effective registrationJul 29, 2025Offer documentSEC
POS AM · Amendment to an effective registrationJul 29, 2025Offer documentSEC
POS AM · Amendment to an effective registrationJul 29, 2025Offer documentSEC
S-8 POSJul 25, 2025Offer documentSEC
S-8 POSJul 25, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 30, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 30, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 10, 2025Big-stake noticeSEC
8-K · Current reportJan 16, 2025Current reportSEC
8-K · Current reportDec 20, 2024Meeting outcomeSEC
DEF 14A · Proxy statementNov 25, 2024Meeting noticeSEC
8-K/A · Current report, amendedNov 19, 2024Material contractSEC
10-Q · Quarterly reportNov 19, 2024Quarterly reportSEC
NT 10-Q · Late filing noticeNov 14, 2024Explanation requestSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
PRE 14A · Preliminary proxy statementNov 12, 2024Meeting noticeSEC
SC 13D/A · Big-stake notice, amendedNov 7, 2024Big-stake noticeSEC
8-K · Current reportNov 6, 2024Management or board changeSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedNov 5, 2024Big-stake noticeSEC
DEF 14A · Proxy statementOct 11, 2024Meeting noticeSEC
25Oct 7, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedOct 2, 2024Big-stake noticeSEC
PRE 14A · Preliminary proxy statementOct 1, 2024Meeting noticeSEC
8-K · Current reportOct 1, 2024ResultsSEC
10-K · Annual reportSep 30, 2024Annual reportSEC
8-K · Current reportAug 27, 2024Current reportSEC
8-K · Current reportJul 15, 2024FinancingSEC
EFFECT · Notice that a registration is effectiveJul 1, 2024Other filingsSEC
424B3 · ProspectusJun 28, 2024Offer documentSEC
CORRESP · Letter to the SECJun 26, 2024Other filingsSEC
S-3/A · Registration statement, amendedJun 25, 2024Offer documentSEC
8-K/A · Current report, amendedJun 25, 2024Current reportSEC
8-K · Current reportJun 24, 2024Current reportSEC
8-K · Current reportJun 24, 2024Current reportSEC
8-K · Current reportJun 17, 2024Current reportSEC
S-3/A · Registration statement, amendedJun 14, 2024Offer documentSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
8-K · Current reportJun 12, 2024Management or board changeSEC
UPLOAD · Letter from the SECJun 11, 2024Other filingsSEC
S-3 · Registration statementJun 5, 2024Offer documentSEC
3 · Initial statement of ownershipJun 5, 2024Insider tradeSEC
8-K · Current reportMay 28, 2024Management or board changeSEC
424B5 · ProspectusMay 15, 2024Offer documentSEC
8-K · Current reportMay 15, 2024Material contractSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
424B3 · ProspectusMay 7, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 30, 2024Other filingsSEC
4 · Change in ownershipApr 26, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedApr 26, 2024Big-stake noticeSEC
8-K · Current reportApr 26, 2024Material contractSEC
CORRESP · Letter to the SECApr 25, 2024Other filingsSEC
UPLOAD · Letter from the SECApr 25, 2024Other filingsSEC
8-K · Current reportApr 23, 2024Material contractSEC
S-3 · Registration statementApr 17, 2024Offer documentSEC
8-K · Current reportApr 10, 2024FinancingSEC
8-K · Current reportApr 9, 2024Material contractSEC
424B5 · ProspectusApr 9, 2024Offer documentSEC
8-K · Current reportApr 8, 2024Current reportSEC
SC 13G · Big-stake noticeApr 4, 2024Big-stake noticeSEC
DEF 14A · Proxy statementMar 29, 2024Meeting noticeSEC
8-K · Current reportMar 29, 2024Material contractSEC
SC 13D/A · Big-stake notice, amendedMar 21, 2024Big-stake noticeSEC
PRE 14A · Preliminary proxy statementMar 19, 2024Meeting noticeSEC
8-K · Current reportMar 14, 2024Current reportSEC
8-K · Current reportMar 13, 2024Material contractSEC
8-K · Current reportMar 4, 2024Current reportSEC
8-K · Current reportFeb 29, 2024Current reportSEC
8-K · Current reportFeb 15, 2024ResultsSEC
10-Q · Quarterly reportFeb 14, 2024Quarterly reportSEC
8-K · Current reportFeb 9, 2024Current reportSEC
8-K · Current reportJan 17, 2024Current reportSEC
8-K · Current reportJan 10, 2024Current reportSEC
8-K · Current reportDec 29, 2023Current reportSEC
8-K · Current reportDec 18, 2023FinancingSEC
8-K · Current reportDec 18, 2023Meeting outcomeSEC
DEFA14A · Additional proxy materialDec 8, 2023Meeting noticeSEC
8-K · Current reportDec 8, 2023Management or board changeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
ARS · Annual report to shareholdersNov 17, 2023Annual reportSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
DEFR14ANov 13, 2023Meeting noticeSEC
DEF 14A · Proxy statementNov 13, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementNov 3, 2023Meeting noticeSEC
8-K · Current reportOct 31, 2023Current reportSEC
8-K · Current reportOct 24, 2023Management or board changeSEC
8-K · Current reportOct 17, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveOct 10, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveOct 10, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveOct 10, 2023Other filingsSEC
10-K/A · Annual report, amendedOct 5, 2023Annual reportSEC
CORRESP · Letter to the SECOct 5, 2023Other filingsSEC
8-K · Current reportOct 3, 2023Current reportSEC
RW WDOct 2, 2023Other filingsSEC
CORRESP · Letter to the SECOct 2, 2023Other filingsSEC
RW · Request to withdraw a registrationOct 2, 2023Other filingsSEC
UPLOAD · Letter from the SECOct 2, 2023Other filingsSEC
CORRESP · Letter to the SECSep 29, 2023Other filingsSEC
8-K · Current reportSep 28, 2023ResultsSEC
S-3 · Registration statementSep 28, 2023Offer documentSEC
POS AM · Amendment to an effective registrationSep 28, 2023Offer documentSEC
POS AM · Amendment to an effective registrationSep 28, 2023Offer documentSEC
S-8 · Registration statement for employee plansSep 28, 2023Offer documentSEC
10-K · Annual reportSep 28, 2023Annual reportSEC
8-K · Current reportSep 22, 2023Current reportSEC
3 · Initial statement of ownershipSep 12, 2023Insider tradeSEC
8-K · Current reportSep 8, 2023Management or board changeSEC
8-K · Current reportAug 21, 2023Current reportSEC
8-K · Current reportJul 17, 2023Current reportSEC
4 · Change in ownershipJul 11, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2023Insider tradeSEC
8-K · Current reportJul 3, 2023Management or board changeSEC
3 · Initial statement of ownershipJul 3, 2023Insider tradeSEC
8-K · Current reportJul 3, 2023Current reportSEC
6-K · Report of a foreign issuerJun 30, 2023Current reportSEC
6-K · Report of a foreign issuerJun 9, 2023Current reportSEC
6-K · Report of a foreign issuerJun 9, 2023Current reportSEC
6-K · Report of a foreign issuerMay 22, 2023Current reportSEC
6-K · Report of a foreign issuerMay 11, 2023Current reportSEC
6-K · Report of a foreign issuerMay 11, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveMay 11, 2023Other filingsSEC
424B3 · ProspectusMay 10, 2023Offer documentSEC
CORRESP · Letter to the SECMay 8, 2023Other filingsSEC
UPLOAD · Letter from the SECMay 5, 2023Other filingsSEC
F-3 · Registration statementMay 2, 2023Offer documentSEC
6-K · Report of a foreign issuerMar 30, 2023Current reportSEC
6-K · Report of a foreign issuerMar 27, 2023Current reportSEC
6-K · Report of a foreign issuerMar 21, 2023Current reportSEC
6-K · Report of a foreign issuerMar 10, 2023Current reportSEC
SC 13D · Big-stake noticeFeb 17, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13D · Big-stake noticeFeb 10, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 8, 2023Current reportSEC
6-K · Report of a foreign issuerDec 20, 2022Current reportSEC
6-K · Report of a foreign issuerNov 30, 2022Current reportSEC
6-K · Report of a foreign issuerNov 29, 2022Current reportSEC
6-K · Report of a foreign issuerNov 22, 2022Current reportSEC
20-F · Annual reportOct 31, 2022Annual reportSEC
6-K · Report of a foreign issuerOct 25, 2022Current reportSEC
6-K · Report of a foreign issuerSep 21, 2022Current reportSEC
6-K · Report of a foreign issuerAug 17, 2022Current reportSEC
EFFECT · Notice that a registration is effectiveAug 3, 2022Other filingsSEC
POS AM · Amendment to an effective registrationAug 1, 2022Offer documentSEC
20-F/A · Annual report, amendedAug 1, 2022Annual reportSEC
6-K · Report of a foreign issuerJun 30, 2022Current reportSEC
6-K · Report of a foreign issuerJun 27, 2022Current reportSEC
EFFECT · Notice that a registration is effectiveJun 7, 2022Other filingsSEC
424B3 · ProspectusJun 6, 2022Offer documentSEC
CORRESP · Letter to the SECJun 2, 2022Other filingsSEC
UPLOAD · Letter from the SECJun 1, 2022Other filingsSEC
F-3 · Registration statementMay 27, 2022Offer documentSEC
SC 13G/A · Big-stake notice, amendedMay 27, 2022Big-stake noticeSEC
SC 13G · Big-stake noticeMay 27, 2022Big-stake noticeSEC
6-K/A · Report of a foreign issuer, amendedApr 29, 2022Current reportSEC
6-K · Report of a foreign issuerApr 1, 2022Current reportSEC
6-K · Report of a foreign issuerMar 31, 2022Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2022Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 11, 2022Big-stake noticeSEC
UPLOAD · Letter from the SECFeb 1, 2022Other filingsSEC
CORRESP · Letter to the SECJan 27, 2022Other filingsSEC
20-F/A · Annual report, amendedJan 27, 2022Annual reportSEC
UPLOAD · Letter from the SECJan 24, 2022Other filingsSEC
6-K · Report of a foreign issuerDec 20, 2021Current reportSEC
6-K · Report of a foreign issuerDec 7, 2021Current reportSEC
6-K · Report of a foreign issuerNov 30, 2021Current reportSEC
20-F · Annual reportOct 21, 2021Annual reportSEC

This page holds 200 of 233 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Renalytix PLC’s releases · as of Sep 28, 2026

Common shares
670,459,333
Fully diluted
670,459,333

Fully diluted

LineSharesAs of
Common shares670,459,333Sep 28, 2026

Share count over time

CountShares
Nov 22, 2026670,459,333
Sep 28, 2026423,376,193
Sep 28, 2026417,040,486
Jun 30, 2026409,540,486

Open Cap table

Shareholders

HolderStakeSharesDate
JEFFERSON RIVER CAPITAL LLC4.50%19.6MNov 4, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Timothy J Scannell
Other companies: Masimo Corporation (Director · Since at least Oct 16, 2024); NovoCure Limited (Director · Since at least Feb 5, 2021); Insulet Corporation (Director · Since at least Aug 12, 2014); EXACT Sciences Corporation (Director · Oct 31, 2023 – Oct 31, 2023 · Past); Molekule Group Inc. (Director · May 11, 2022 – Jun 1, 2022 · Past); Stryker Corporation (President and COO · Dec 1, 2008 – Aug 1, 2021 · Past)
Director · Jul 1, 2023 – Jul 1, 2023 · Past
Catherine Coste
Other companies: BioLife Solutions, Inc. (Director · Since at least Mar 18, 2025); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); Biomerica, Inc. (Director · Oct 26, 2020 – Dec 13, 2024 · Past)
Director · Since at least Jul 1, 2023
Thomas H McLain
Other companies: Aspira Women's Health Inc. (President & CEO · Mar 18, 2013 – Mar 27, 2014 · Past); Eastman Chemical Company (Director · Apr 3, 2006 – Nov 30, 2011 · Past); Vaxart, Inc. (Chairman, CEO & President, Director · Dec 31, 2005 – Dec 30, 2006 · Past)
President · Jul 1, 2023 – Jul 10, 2023 · Past
Daniel J Levangie
Other companies: EXACT Sciences Corporation (Director · Since at least Jul 23, 2015); Insulet Corporation (EVP & President, Drug Delivery · Feb 23, 2016 – Apr 30, 2016 · Past)
Director · Jul 1, 2023 – Nov 20, 2023 · Past
Howard Doran Jr
Other companies: LipoScience Inc (President and CEO, Director · Feb 3, 2014 – Nov 20, 2014 · Past); Hologic Inc (SVP, Diagnostics Products · Oct 22, 2007 – Mar 12, 2010 · Past)
Chief Business Officer · Sep 1, 2023 – Nov 20, 2023 · Past
Erik Lium
Other companies: Trellus Health PLC (Non-Executive Director · Since at least Nov 5, 2026)
Board Member · Since at least Jul 1, 2023
Joel R. Jung
Other companies: Minerva Surgical, Inc. (CFO · Oct 21, 2021 – May 2, 2022 · Past)
MBA, Interim CFO · Since at least May 27, 2024
O James Sterling
Other companies: Bluebird bio Inc (Chief Financial Officer · Since at least Jun 10, 2024)
Chief Financial Officer · Jul 1, 2023 – Jul 6, 2023 · Past
Chirag R ParikhDirector · Jul 1, 2023 – Nov 20, 2023 · Past
Christopher MillsDirector · Since at least Jul 1, 2023
All 17 people
PersonSeat
Elise WilfingerChief Strategy & Marketing Officer · Since at least May 12, 2026
Fergus FlemingCTO · Since at least Jul 1, 2023
Howard DoranPresident · Since at least Dec 30, 2024
James McCulloughMBA, CEO · Since at least Jul 1, 2023
Julian BainesChairman · Since at least Sep 3, 2026
Michael J. DonovanChief Medical Officer · Since at least Jul 1, 2023
Robert NaylorDirector · Since at least Dec 9, 2025

Open People

Log in to ask 6ix AI your own questions about Renalytix PLC.